CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01834248
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:34.068478+00:00
Published At: 2022-07-22T00:00:00+00:00
Record Updated At: 2022-07-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Refractory Anemia With Excess Blasts in Transformation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-07-22"
protocolSection.identificationModule.nctId: "NCT01834248"
protocolSection.identificationModule.officialTitle: "A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2\u0027Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.